X

Trial Profile

Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary)
Indications Advanced breast cancer; Brain metastases; Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms Saci-IO TNBC

Most Recent Events

15 Apr 2024 Planned End Date changed from 1 Apr 2027 to 1 Apr 2029.
15 Apr 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2026.
20 Dec 2021 Planned End Date changed from 1 Jun 2026 to 1 Apr 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com